Live Breaking News & Updates on European Union The Prospectus Directive

Stay updated with breaking news from European union the prospectus directive. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cosmo announces the start of trading of its shares on XETRA


Cosmo announces the start of trading of its shares on XETRA
Search jobs
Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous
19-Apr-2021 / 06:00 GMT/BST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
Dublin, Ireland - 19 April 2021: Shares of Cosmo Pharmaceuticals NV ( Cosmo ) (SIX: COPN), which have traded on the Swiss Stock Exchange since 2007, will now also trade on XETRA in Frankfurt, Germany. Trading will commence today, Monday, at 9:00am CEST under tickersymbol C43. COSMO PHARMACEUT. EO-,26 ISIN: NL0011832936 | WKN: A2AJ68 | Ric: C43 | Type: Equity. The listing on XETRA, Germany s most important stock exchange, is aimed at providing easier access to European investors, significantly improving the visibility of the Company on the capital markets and increasing the overall liquidity in the trading of Cosmo s shares.  ....

United States , United Kingdom , Noord Holland , Falk Gmbh , Niall Donnelly , Cosmo Pharmaceuticals , Swiss Stock Exchange , Drug Administration , Financial Services , Swiss Exchange , Cosmo Pharmaceuticalsnv Key , European Union The Prospectus Directive , Cosmo Pharmaceuticals Nv , Redhill Biopharma Ltd , Designated Sponsors , United Arab Emirate , Methylene Blue , Cassiopea Spa , Redhill Biopharma , General Meeting , Swiss Code , Markets Act , Financial Promotion , European Union , European Economic Area , Prospectus Directive ,

Cosmo announces FDA approval of GI Genius intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy


(1)
DUBLIN, April 12, 2021 /PRNewswire/ Cosmo Pharmaceuticals NV (SIX: COPN) today announced the FDA approval of GI Genius intelligent endoscopy system, its revolutionary device for lesion detection during colonoscopy.
The GI Genius module FDA approval marks a pivotal milestone for Cosmo after more than 10 years of research and investments focused to generate disruptive innovations in the field of colon s disease and optimization of the colonoscopy procedure. The development of GI Genius intelligent endoscopy module has been possible thanks to the leadership position of Cosmo, its unique proprietary library of high-definition loss-less videos of colonoscopies and its proprietary software and algorithms. The device is the first of its kind to obtain the FDA approval through the De Novo application. The device operates in real time to assist the endoscopist in the detection of lesions, is very simple to use and is compatible with all endoscopes. Cosmo is the sole manufactu ....

United States , United Kingdom , Noord Holland , Fredc Andersen , Michael Wallace , Mauro Ajani , Falk Gmbh , Niall Donnelly , Cosmo Pharmaceuticals , Financial Services , Swiss Exchange , Prnewswire Cosmo Pharmaceuticals , European Union The Prospectus Directive , Redhill Biopharma Ltd , Mayo Clinic , Gastrointestinal Endoscopy , Redhill Biopharma , General Meeting , Swiss Code , Markets Act , Financial Promotion , European Union , European Economic Area , Prospectus Directive , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் ,